Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II tocilizumab in anti-TNF refractory JIA-associated uveitis
2015-001323-23Phase 2Completed
- Sponsor
- University Hospitals Bristol and Weston NHS Foundation Trust
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in juvenile idiopathic arthritis-associated uveitis (JIA-U) and uveitis, sponsored by University Hospitals Bristol and Weston NHS Foundation Trust. Primary endpoint: Clinical response of uveitis to tocilizumab + methotrexate. Started May 2015; status: completed.
02
Drugs
tocilizumab
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)uveitis
Beyond the preview
Go deeper on 2015-001323-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001323-23.